A First in the US - Revolutionary Non -Surgical Treatment for Stress Urinary Incontinence
May 4, 2020
Dr. Lucente, who participated in the original clinical trials, was the first physician to perform Bulkamid Transurethral Injections in the United States. After joining an elite group of international physicians in Helsinki, Finland for an educational workshop on how to best teach the procedure to other physicians, Dr Lucente administered the first U.S.A. injections at our Institute in mid-March.
Bulkamid is a recent FDA approved groundbreaking, non-surgical treatment for stress urinary incontinence. Stress urinary incontinence is the involuntary loss of urine associated with physical activity or “stress” activities such as coughing, sneezing, or laughing. It is not a bladder problem, but rather a failure of the little tubular structure that urine travels through when you void (the urethra) to maintain a water-tight seal, when pressure from your upper body compresses down onto the bladder. It is one of the most prevalent forms of incontinence among women, occurring in an estimated 25 million adult women in the U.S. Unfortunately, most women do not seek medical treatment to easily resolve this leakage, but rather use daily pads to deal with the problem.
Bulkamid, a urethral bulking agent that is totally unique to its class, is delivered through a transurethral injection system that can be administered safely in a non-hospital setting. The soft gel-like material acts to “cushion” the urethral tissues near the bladder opening to help prevent leakage in women suffering from stress urinary incontinence.
Bulking agents have been used for years to expand the lining of the urethra in order to help alleviate stress incontinence. What makes Bulkamid unique is that the injectable hydrogel (mostly water) will not breakdown, or “shrink,” it will not migrate, or seep out of the injection site upon implantation. Most importantly, the durability of Bulkamid is measured in years, rather than rather than months like other bulking agents. Several large clinical studies measuring the outcomes in patients who have received Bulkamid have demonstrated that, the safety, efficacy, and durability to be very favorable. Bulkamid is effective in 80-85% of patients and has demonstrated durability as long as seven years. Durability was measured in both the results of the patients still being “dry” as well as ultrasound verification that the urethral “cushions” were still the same, both in size and in location.
Bulkamid is an excellent alternative for women who are seeking a very safe and long-term relief from SUI and no longer want to wear absorbent pads but do not wish to have a traditional surgical procedure but Please contact the office to schedule an evaluation 610-435-9575.
The Institute for Female Pelvic Medicine is on Facebook